Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Cancer Res. 2011 Nov 11;72(1):294–303. doi: 10.1158/0008-5472.CAN-11-3240

Fig. 1. Bcl-2 inhibitor ABT-737 synergizes with small molecule inhibitors of Pim protein kinases to overcome cell resistance mediated by Bcl-2 overexpression.

Fig. 1

A, LNCaP cells were treated with DMSO, ABT-737 (3 µM), SMI-4a (10 µM), Pimi-14j (10 µM), or combinations for 16h. The percentage of cell death was evaluated using trypan blue staining assay (mean +/− SD, n=6). B, Whole cell extracts from the above treatments were analyzed by immunoblotting with the antibodies shown. C, PC-3 cells were transfected with HA-tagged Bcl-2 plasmid and individual clones selected with 1 mg/ml G418 treatment. Parental PC-3 (P) cells and selected individual clones were treated with DMSO, SMI-4a, ABT-737 or combinations of both agents at the indicated doses. The percentage of viable cells after 24h of treatment was determined by MTT assay (mean +/− SD, n=4).